Free Trial
→ If you keep cash in a U.S. bank account… read this NOW (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:DWTX

Dogwood Therapeutics Q3 2026 Earnings Date & Estimates

Dogwood Therapeutics logo
$1.40 -0.01 (-0.71%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.45 +0.05 (+3.50%)
As of 10/9/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Dogwood Therapeutics is expected to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for November 10, 2026 at 12:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
12:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Dogwood Therapeutics in Q3 2026

Dogwood Therapeutics is expected to post earnings of -$0.15 per share. In the same quarter a year earlier Dogwood Therapeutics reported -$8.20 per share. Dogwood Therapeutics last reported on August 13, 2026, posting -$0.34 per share and missing the -$0.14 consensus estimate. Dogwood Therapeutics has beaten the consensus EPS estimate in 2 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.15
Prior-Year EPS
-$8.20

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.34 (Missed by -$0.20)
EPS Beat Rate
2 of last 8 quarters

Prepare for the Q3 2026 Call

Dogwood Therapeutics Q3 2026 Earnings FAQ

Dogwood Therapeutics (NASDAQ:DWTX) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Dogwood Therapeutics' Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Dogwood Therapeutics to post earnings of -$0.15 per share for Q3 2026.

Dogwood Therapeutics Earnings Headlines

Dogwood Therapeutics (NASDAQ:DWTX) Stock Price Down 5.9% - Time to Sell?
October 8 at 2:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31098031
Dogwood to Participate in the 2026 Maxim Growth Summit
October 6, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/06/3375523/0/en/dogwood-to-participate-in-the-2026-maxim-growth-summit.html
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.tc pixel
October 10 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Dogwood Therapeutics Stock Price History
September 15, 2026  |  investing.comhttps://www.investing.com/equities/virios-therapeutics-llc-historical-data
Dogwood Completes Enrollment In Halneuron Phase 2b CINP Trial; Topline Data Due November
September 14, 2026  |  rttnews.comhttps://www.rttnews.com/3690763/dogwood-completes-enrollment-in-halneuron-phase-2b-cinp-trial-topline-data-due-november.aspx
Dogwood Announces Completion of Enrollment in Ongoing Halneuron® Phase 2b Trial
September 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/14/3361120/0/en/dogwood-announces-completion-of-enrollment-in-ongoing-halneuron-phase-2b-trial.html
See More Dogwood Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Dogwood Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dogwood Therapeutics and other key companies, straight to your email.

About Dogwood Therapeutics

Dogwood Therapeutics (NASDAQ:DWTX). is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with herpesvirus reactivation. The company’s research is aimed at addressing chronic conditions for which viral activity may contribute to symptoms and disease progression.

Dogwood’s lead investigational product is IMC-1, a fixed-dose combination of famciclovir, an antiviral medicine, and celecoxib, an anti-inflammatory drug. The therapy has been studied as a potential treatment for fibromyalgia, and the company has also evaluated its broader application in conditions such as long COVID.

The company was formerly known as Virios Therapeutics and adopted the Dogwood Therapeutics name as it expanded its focus on antiviral drug development. Its programs remain investigational and are subject to clinical testing and regulatory review. Publicly available information about its geographic operations and leadership is limited.

View Dogwood Therapeutics Profile
Earnings Tools